INVESTIGADORES
RABINOVICH Gabriel Adrian
artículos
Título:
Dendritic Cells Exposed to Triiodothyronine Deliver Pro-Inflammatory Signals and Amplify IL-17-Driven Immune Responses
Autor/es:
VANINA A ALAMINO; MARIA DEL MAR MONTESINO; MARIA FLORENCIA SOLER; LUCILA GIUSIANO; NICOLAS GIGENA; LAURA FOZZATTI; SEBASTIAN M MALLER; SANTIAGO MENDEZ HUERGO; GABRIEL ADRIAN RABINOVICH; CLAUDIA PELLIZAS
Revista:
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY : INTERNATIONAL JOURNAL OF EXPERIMENTAL CELLULAR PHYSIOLOGY, BIOCHEMISTRY, AND PHARMACOLOGY.
Editorial:
KARGER
Referencias:
Lugar: Basel; Año: 2019 vol. 52 p. 354 - 367
ISSN:
1015-8987
Resumen:
AbstractBackground/Aims: Although a cross-talk between immune and endocrine systems has been well established, the precise pathways by which these signals co-regulate pro- and antiinflammatory responses on antigen-presenting cells remain poorly understood. In this work we investigated the mechanisms by which triiodothyronine (T3) controls T cell activity via dendritic cell (DC) modulation. Methods: DCs from wild-type (WT) and IL-6-deficient micewere pulsed with T3. Cytokine production and programmed death protein ligands (PD-L) 1 and 2 expression were assayed by flow cytometry and ELISA. Interferon-regulatory factor-4 (IRF- 4) expression was evaluated by RT-qPCR and flow cytometry. The ability of DCs to stimulate allogenic splenocytes was assessed in a mixed lymphocyte reaction and the different profile markers were analyzed by flow cytometry and ELISA. For in vivo experiments, DCs treated with ovalbumin and T3 were injected into OTII mice. Proliferation, cytokine production, Frequency of FoxP3+ regulatory T (Treg) cells and PD-1+ cells were determined by MTT assay, ELISA and flow cytometry, respectively. Results: T3 endows DCs with pro-inflammatory potential capable of generating IL-17-dominant responses and down-modulating expression of PD-L1 and 2. T3-stimulated WT-DCs increased the proportion of IL-17-producing splenocytes, an effect which was eliminated when splenocytes were incubated with T3-treated DCs derived from IL-6-deficient mice. Enhanced IL-17 expression was recorded in both, CD4- and CD4+ populations and involved the IRF-4 pathway. Particularly, gammadelta-T cells but not natural killer (NK),